Avid Bioservices, Inc. revised revenue guidance for the full fiscal year 2024. The company is adjusting revenue guidance for full fiscal year 2024 to $137 million to $147 million, previously $145 million and $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.2 USD | +4.43% | +5.02% | +41.54% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.54% | 584M | |
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-12.32% | 33.03B | |
+54.25% | 24.68B | |
-17.39% | 15.12B | |
-9.14% | 12.81B | |
-10.48% | 11.79B | |
-42.45% | 11.64B | |
+7.04% | 8.9B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024